GGrantIndex
← Leaderboards

Douglas A Marchuk

Duke University

$20,574,970
Attributed
$26,770,926
Total exposure
19
Grants
13
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$39,709,821 · 20

By mechanism

P01$17,300,454 · 6
R01$13,724,835 · 7
R44$3,287,712 · 1
T32$2,658,375 · 1
U54$1,058,371 · 1
P30$749,800 · 1

Top collaborators

Most similar at Duke University

Same institution · by research overlap

Others in their field

Top investigators on “Phenotype

Research focus

PhenotypeGenesBlood VesselsMolecularBrainMouse ModelPathogenesisGeneticMutationOperative Surgical ProceduresLesionSignal TransductionEventEndothelial CellsStrokeSomatic MutationClinically RelevantProteinsGene MutationCerebral Cavernous MalformationsSignal PathwayBaseLeadHemorrhage

Grant awards (98)

Developmental Origins of the Sturge Weber Syndrome Somatic Mutation$201,875
R21 · FY2025 · HD · contact PI
Signaling Aberrations and Cerebral Cavernous Malformation Pathogenesis$1,249,844
P01 · FY2024 · NS · contact PI
Somatic mutation(s) and cellular changes in CCM pathogenesis$321,343
P01 · FY2024 · NS · contact PI
Administrative Core$35,177
P01 · FY2024 · NS · contact PI
Signaling Aberrations and Cerebral Cavernous Malformation Pathogenesis$1,295,444
P01 · FY2023 · NS · contact PI
Somatic mutation(s) and cellular changes in CCM pathogenesis$415,446
P01 · FY2023 · NS · contact PI
Administrative Core$36,265
P01 · FY2023 · NS · contact PI
Signaling Aberrations and Cerebral Cavernous Malformation Pathogenesis$1,303,254
P01 · FY2022 · NS · contact PI
Novel Targets for Stroke Intervention - Gene Discovery for Modulators of Infarction$638,289
R01 · FY2022 · NS · contact PI
Somatic mutation(s) and cellular changes in CCM pathogenesis$331,345
P01 · FY2022 · NS · contact PI
Administrative Core$36,271
P01 · FY2022 · NS · contact PI
Signaling Aberrations and Cerebral Cavernous Malformation Pathogenesis$1,310,712
P01 · FY2021 · NS · contact PI
Novel Targets for Stroke Intervention - Gene Discovery for Modulators of Infarction$638,289
R01 · FY2021 · NS · contact PI
Somatic mutation(s) and cellular changes in CCM pathogenesis$331,316
P01 · FY2021 · NS · contact PI
Administrative Core$36,267
P01 · FY2021 · NS · contact PI
Signaling Aberrations and Cerebral Cavernous Malformation Pathogenesis$1,353,471
P01 · FY2020 · NS · contact PI
Novel Targets for Stroke Intervention - Gene Discovery for Modulators of Infarction$638,289
R01 · FY2020 · NS · contact PI
Somatic mutation(s) and cellular changes in CCM pathogenesis$337,398
P01 · FY2020 · NS · contact PI
Administrative Core$49,553
P01 · FY2020 · NS · contact PI
Signaling Aberrations and Cerebral Cavernous Malformation Pathogenesis$1,260,831
P01 · FY2019 · NS · contact PI
Novel Targets for Stroke Intervention - Gene Discovery for Modulators of Infarction$639,088
R01 · FY2019 · NS · contact PI
Molecular genetic alterations contributing to CCM pathogenesis$295,125
P01 · FY2019 · NS · contact PI
Administrative Core$48,538
P01 · FY2019 · NS · contact PI
Signaling Aberrations and Cerebral Cavernous Malformation Pathogenesis$1,268,359
P01 · FY2018 · NS · contact PI
Novel Targets for Stroke Intervention - Gene Discovery for Modulators of Infarction$650,198
R01 · FY2018 · NS · contact PI
Molecular genetic alterations contributing to CCM pathogenesis$299,961
P01 · FY2018 · NS · contact PI
Administrative Core$49,522
P01 · FY2018 · NS · contact PI
Development of BA-1049 for treatment of cerebral cavernous malformation$1,576,432
R44 · FY2017 · NS
Signaling Aberrations and Cerebral Cavernous Malformation Pathogenesis$1,275,792
P01 · FY2017 · NS · contact PI
Molecular genetic alterations contributing to CCM pathogenesis$316,936
P01 · FY2017 · NS · contact PI
Administrative Core$52,516
P01 · FY2017 · NS · contact PI
Development of BA-1049 for treatment of cerebral cavernous malformation$1,430,655
R44 · FY2016 · NS
Signaling Aberrations and Cerebral Cavernous Malformation Pathogenesis$1,282,511
P01 · FY2016 · NS · contact PI
Rock Inhibition as Therapy for Cerebral Cavernous Malformation$433,569
R01 · FY2016 · NS
Molecular genetic alterations contributing to CCM pathogenesis$309,217
P01 · FY2016 · NS · contact PI
Development of BA-1049 for treatment of cerebral cavernous malformation$280,625
R44 · FY2016 · NS
Functional Characterization of the GNAQ somatic mutation causing Sturge Weber syndrome$238,500
R21 · FY2016 · NS · contact PI
Administrative Core$51,410
P01 · FY2016 · NS · contact PI
Signaling Aberrations and Cerebral Cavernous Malformation Pathogenesis$1,338,677
P01 · FY2015 · NS · contact PI
Rock Inhibition as Therapy for Cerebral Cavernous Malformation$455,117
R01 · FY2015 · NS
Molecular genetic alterations contributing to CCM pathogenesis$314,822
P01 · FY2015 · NS · contact PI
Functional Characterization of the GNAQ somatic mutation causing Sturge Weber syndrome$198,128
R21 · FY2015 · NS · contact PI
Administrative Core$52,470
P01 · FY2015 · NS · contact PI
Rock Inhibition as Therapy for Cerebral Cavernous Malformation$473,253
R01 · FY2014 · NS
Genetics Training Grant$432,052
T32 · FY2014 · GM · contact PI
Rock Inhibition as Therapy for Cerebral Cavernous Malformation$447,296
R01 · FY2013 · NS
Genetics Training Grant$446,546
T32 · FY2013 · GM · contact PI
Innovative approaches to gauge progression of Sturge-Weber Syndrome$201,682
U54 · FY2013 · NS · contact PI
Rock Inhibition as Therapy for Cerebral Cavernous Malformation$459,797
R01 · FY2012 · NS
Genesis and Progression of Cerebral Cavernous Malformations$457,386
R01 · FY2012 · NS · contact PI
Genetics Training Grant$446,546
T32 · FY2012 · GM · contact PI
Natural genetic variation regulating infarct volume$386,100
R01 · FY2012 · HL · contact PI
Genesis and Progression of Cerebral Cavernous Malformations$476,791
R01 · FY2011 · NS · contact PI
Genetics Training Grant$441,880
T32 · FY2011 · GM · contact PI
Natural genetic variation regulating infarct volume$390,000
R01 · FY2011 · HL · contact PI
Innovative approaches to gauge progression of Sturge-Weber Syndrome$277,465
U54 · FY2011 · NS · contact PI
Genesis and Progression of Cerebral Cavernous Malformations$479,794
R01 · FY2010 · NS · contact PI
Genetics Training Grant$437,344
T32 · FY2010 · GM · contact PI
Identification of genetics modifiers of heart diease$390,000
R01 · FY2010 · HL · contact PI
Natural genetic variation regulating infarct volume$390,000
R01 · FY2010 · HL · contact PI
Innovative approaches to gauge progression of Sturge-Weber Syndrome$283,183
U54 · FY2010 · NS · contact PI
Genesis and Progression of Cerebral Cavernous Malformations$88,629
R01 · FY2010 · NS · contact PI
Genesis and Progression of Cerebral Cavernous Malformations$484,559
R01 · FY2009 · NS · contact PI
Genetics Training Grant-Year 26$454,007
T32 · FY2009 · GM · contact PI
Identification of genetic modifiers of heart disease$390,000
R01 · FY2009 · HL · contact PI
Natural genetic variation regulating infarct volume$390,000
R01 · FY2009 · HL · contact PI
Innovative approaches to gauge progression of Sturge-Weber Syndrome$296,041
U54 · FY2009 · NS · contact PI
Identification of genetic modifiers of heart disease$390,000
R01 · FY2008 · HL · contact PI
Identification of genetic modifiers of heart disease$389,479
R01 · FY2007 · HL · contact PI
Gene Discovery for Cerebral Cavernous Malformations$314,735
R01 · FY2006 · NS · contact PI
Gene Discovery for Cerebral Cavernous Malformations$322,310
R01 · FY2005 · NS
Gene Discovery for Cerebral Cavernous Malformations$322,310
R01 · FY2004 · NS
GENETICS OF HEREDITARY HEMORRHAGIC TELANGIECTASIA$308,000
R01 · FY2004 · HL
Gene Discovery for Cerebral Cavernous Malformations$322,310
R01 · FY2003 · NS
GENETICS OF HEREDITARY HEMORRHAGIC TELANGIECTASIA$308,000
R01 · FY2003 · HL
Gene Discovery for Cerebral Cavernous Malformations$70,538
R01 · FY2003 · NS
Gene Discovery for Cerebral Cavernous Malformations$334,865
R01 · FY2002 · NS
GENETICS OF HEREDITARY HEMORRHAGIC TELANGIECTASIA$308,000
R01 · FY2002 · HL
Core--Genome facility$187,450
P30 · FY2002 · CA
MODEL OF HEREDIT HEMORRHAG TELANGIECTASIA: MR MICROSCOPY OF ALK 1 KNOCKOUT MICE$0
P41 · FY2002 · RR
MODEL OF HEREDIT HEMORRHAG TELANGIECTASIA: MR MICROSCOPY OF ALK 1 KNOCKOUT MICE$0
P41 · FY2002 · RR
MOLECULAR STUDIES OF DOMINANT AUTOSOMAL SPASTIC PARAPLEGIA (SPG)$0
P01 · FY2002 · NS
MOLECULAR STUDIES OF DOMINANT AUTOSOMAL SPASTIC PARAPLEGIA (SPG)$0
P01 · FY2002 · NS
GENETICS OF HEREDITARY HEMORRHAGIC TELANGIECTASIA$308,000
R01 · FY2001 · HL
MODEL OF HEREDIT HEMORRHAG TELANGIECTASIA: MR MICROSCOPY OF ALK 1 KNOCKOUT MICE$288,015
P41 · FY2001 · RR
MOLECULAR STUDIES OF DOMINANT AUTOSOMAL SPASTIC PARAPLEGIA (SPG)$207,281
P01 · FY2001 · NS
Core--Genome facility$187,450
P30 · FY2001 · CA
Core--Genome facility$187,450
P30 · FY2001 · CA
Core--Genome facility$187,450
P30 · FY2001 · CA
MOLECULAR STUDIES OF DOMINANT AUTOSOMAL SPASTIC PARAPLEGIA (SPG)$0
P01 · FY2001 · NS
MODEL OF HEREDIT HEMORRHAG TELANGIECTASIA: MR MICROSCOPY OF ALK 1 KNOCKOUT MICE$0
P41 · FY2001 · RR
Core--Genome facility$0
P30 · FY2001 · CA
GENETICS OF HEREDITARY HEMORRHAGIC TELANGIECTASIA$229,844
R01 · FY2000 · HL
MOLECULAR STUDIES OF DOMINANT AUTOSOMAL SPASTIC PARAPLEGIA (SPG)$226,099
P01 · FY2000 · NS
MOLECULAR STUDIES OF DOMINANT AUTOSOMAL SPASTIC PARAPLEGIA (SPG)$207,281
P01 · FY2000 · NS
MODEL OF HEREDIT HEMORRHAG TELANGIECTASIA: MR MICROSCOPY OF ALK 1 KNOCKOUT MICE$3,756
P41 · FY2000 · RR
Core--Genome facility$0
P30 · FY2000 · CA
Core--Genome facility$0
P30 · FY2000 · CA